Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance

Marianna Lucafò, Vanessa Bravin, Alberto Tommasini, Stefano Martelossi, Ingrid Rabach, Alessandro Ventura, Giuliana Decorti, Sara De Iudicibus

Research output: Contribution to journalArticle

Abstract

This study evaluates the association between the long noncoding RNA GAS5 levels and the anti-proliferative effect of the glucocorticoid (GC) methylprednisolone (MP) alone and in combination with rapamycin in peripheral blood mononuclear cells (PBMCs) obtained from healthy donors. The effect of MP, rapamycin, and MP plus rapamycin was determined in 17 healthy donors by labelling metabolically active cells with [methyl-3H] thymidine and the expression levels of GAS5 gene were evaluated by real-time RT-PCR TaqMan analysis. We confirmed a role for GAS5 in modulating GC response: poor responders presented higher levels of GAS5 in comparison with good responders. Interestingly, when PBMCs were treated with the combination of rapamycin plus MP, the high levels of GAS5 observed for each drug in the MP poor responders group decreased in comparison with rapamycin (P value = 0.0134) or MP alone (P value = 0.0193). GAS5 is involved in GC resistance and co-treatment of rapamycin with GCs restores GC effectiveness in poor responders through the downregulation of the long noncoding RNA. GAS5 could be considered a biomarker to personalize therapy and a novel therapeutic target useful for the development of new pharmacological approaches to restore GC sensitivity.

Original languageEnglish
Pages (from-to)602-605
Number of pages4
JournalClinical and Experimental Pharmacology and Physiology
Volume43
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Methylprednisolone
Sirolimus
Glucocorticoids
Long Noncoding RNA
Blood Cells
Thymidine
Glucocorticoid Receptor Deficiency
Real-Time Polymerase Chain Reaction
Down-Regulation
Biomarkers
Pharmacology
Therapeutics
Pharmaceutical Preparations
Genes

Keywords

  • GAS5
  • Glucocorticoids
  • Long noncoding RNA
  • Methylprednisolone
  • Rapamycin

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Pharmacology

Cite this

Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance. / Lucafò, Marianna; Bravin, Vanessa; Tommasini, Alberto; Martelossi, Stefano; Rabach, Ingrid; Ventura, Alessandro; Decorti, Giuliana; De Iudicibus, Sara.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 43, No. 6, 01.06.2016, p. 602-605.

Research output: Contribution to journalArticle

Lucafò, Marianna ; Bravin, Vanessa ; Tommasini, Alberto ; Martelossi, Stefano ; Rabach, Ingrid ; Ventura, Alessandro ; Decorti, Giuliana ; De Iudicibus, Sara. / Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance. In: Clinical and Experimental Pharmacology and Physiology. 2016 ; Vol. 43, No. 6. pp. 602-605.
@article{c01f3228ad8a4f10babb678aeb86a790,
title = "Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance",
abstract = "This study evaluates the association between the long noncoding RNA GAS5 levels and the anti-proliferative effect of the glucocorticoid (GC) methylprednisolone (MP) alone and in combination with rapamycin in peripheral blood mononuclear cells (PBMCs) obtained from healthy donors. The effect of MP, rapamycin, and MP plus rapamycin was determined in 17 healthy donors by labelling metabolically active cells with [methyl-3H] thymidine and the expression levels of GAS5 gene were evaluated by real-time RT-PCR TaqMan analysis. We confirmed a role for GAS5 in modulating GC response: poor responders presented higher levels of GAS5 in comparison with good responders. Interestingly, when PBMCs were treated with the combination of rapamycin plus MP, the high levels of GAS5 observed for each drug in the MP poor responders group decreased in comparison with rapamycin (P value = 0.0134) or MP alone (P value = 0.0193). GAS5 is involved in GC resistance and co-treatment of rapamycin with GCs restores GC effectiveness in poor responders through the downregulation of the long noncoding RNA. GAS5 could be considered a biomarker to personalize therapy and a novel therapeutic target useful for the development of new pharmacological approaches to restore GC sensitivity.",
keywords = "GAS5, Glucocorticoids, Long noncoding RNA, Methylprednisolone, Rapamycin",
author = "Marianna Lucaf{\`o} and Vanessa Bravin and Alberto Tommasini and Stefano Martelossi and Ingrid Rabach and Alessandro Ventura and Giuliana Decorti and {De Iudicibus}, Sara",
year = "2016",
month = "6",
day = "1",
doi = "10.1111/1440-1681.12572",
language = "English",
volume = "43",
pages = "602--605",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance

AU - Lucafò, Marianna

AU - Bravin, Vanessa

AU - Tommasini, Alberto

AU - Martelossi, Stefano

AU - Rabach, Ingrid

AU - Ventura, Alessandro

AU - Decorti, Giuliana

AU - De Iudicibus, Sara

PY - 2016/6/1

Y1 - 2016/6/1

N2 - This study evaluates the association between the long noncoding RNA GAS5 levels and the anti-proliferative effect of the glucocorticoid (GC) methylprednisolone (MP) alone and in combination with rapamycin in peripheral blood mononuclear cells (PBMCs) obtained from healthy donors. The effect of MP, rapamycin, and MP plus rapamycin was determined in 17 healthy donors by labelling metabolically active cells with [methyl-3H] thymidine and the expression levels of GAS5 gene were evaluated by real-time RT-PCR TaqMan analysis. We confirmed a role for GAS5 in modulating GC response: poor responders presented higher levels of GAS5 in comparison with good responders. Interestingly, when PBMCs were treated with the combination of rapamycin plus MP, the high levels of GAS5 observed for each drug in the MP poor responders group decreased in comparison with rapamycin (P value = 0.0134) or MP alone (P value = 0.0193). GAS5 is involved in GC resistance and co-treatment of rapamycin with GCs restores GC effectiveness in poor responders through the downregulation of the long noncoding RNA. GAS5 could be considered a biomarker to personalize therapy and a novel therapeutic target useful for the development of new pharmacological approaches to restore GC sensitivity.

AB - This study evaluates the association between the long noncoding RNA GAS5 levels and the anti-proliferative effect of the glucocorticoid (GC) methylprednisolone (MP) alone and in combination with rapamycin in peripheral blood mononuclear cells (PBMCs) obtained from healthy donors. The effect of MP, rapamycin, and MP plus rapamycin was determined in 17 healthy donors by labelling metabolically active cells with [methyl-3H] thymidine and the expression levels of GAS5 gene were evaluated by real-time RT-PCR TaqMan analysis. We confirmed a role for GAS5 in modulating GC response: poor responders presented higher levels of GAS5 in comparison with good responders. Interestingly, when PBMCs were treated with the combination of rapamycin plus MP, the high levels of GAS5 observed for each drug in the MP poor responders group decreased in comparison with rapamycin (P value = 0.0134) or MP alone (P value = 0.0193). GAS5 is involved in GC resistance and co-treatment of rapamycin with GCs restores GC effectiveness in poor responders through the downregulation of the long noncoding RNA. GAS5 could be considered a biomarker to personalize therapy and a novel therapeutic target useful for the development of new pharmacological approaches to restore GC sensitivity.

KW - GAS5

KW - Glucocorticoids

KW - Long noncoding RNA

KW - Methylprednisolone

KW - Rapamycin

UR - http://www.scopus.com/inward/record.url?scp=84964848879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964848879&partnerID=8YFLogxK

U2 - 10.1111/1440-1681.12572

DO - 10.1111/1440-1681.12572

M3 - Article

AN - SCOPUS:84964848879

VL - 43

SP - 602

EP - 605

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 6

ER -